Unique ID issued by UMIN | UMIN000048925 |
---|---|
Receipt number | R000055568 |
Scientific Title | A Phase2 Trial of Total Parietal Peritonectomy in Primary Debulking Surgery for Advanced Ovarian Neoplasm |
Date of disclosure of the study information | 2022/09/20 |
Last modified on | 2022/10/10 08:06:53 |
A study on efficacy and safety of total peritoneal resection in surgical treatment of advanced ovarian cancer
TPP study
A Phase2 Trial of Total Parietal Peritonectomy in Primary Debulking Surgery for Advanced Ovarian Neoplasm
TPP Phase 2 Trial
Japan |
ovarian cancer
Obstetrics and Gynecology |
Malignancy
NO
Patients with stage IIIB-IIIC ovarian cancer with extensive peritoneal dissemination are eligible. We will evaluate the efficacy of total parietal peritonectomy (TPP) in primary debulking surgery (PDS) when complete surgery (no macroscopically residual disease) is performed with multiple organ resection to determine whether TPP improves prognosis . At the same time, we will evaluate the safety of TPP in terms of complications.
If this Phase II study shows that TPP may be effective and the safety profile is acceptable, we will proceed to phase III study.
Safety,Efficacy
Phase II
2-year RFS rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Total Parietal Peritonectomy
18 | years-old | <= |
70 | years-old | >= |
Female
* Primary diagnosis of ovarian cancer FIGO stage IIIB-IIIC
* Macroscopic complete resection is possible with PDS based on preoperative examination, staging laparoscopy, and intraoperative findings during PDS
* Histology is diagnosed as High Grade Serous Carcinoma or Endometrioid Carcinoma by tissue biopsy during staging laparoscopy
* Patients who have given their signed and written informed consent
* Age: 18 - 70 years
* Good performance status (ECOG 0/1)
* Borderline tumors
* There are suspicious lymph nodes (bulky nodes) in preoperative examination and intraoperative findings and systematic retroperitoneal lymphadenectomy is required
* Secondary invasive neoplasms in the last 5 years (However, it is permissible if the possibility of recurrence within 2 years after registration is sufficiently low)
* Neoadjuvant chemotherapy
* Any significant medical reasons, age or performance status that will not
allow to perform the study procedures
* Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
40
1st name | Aikou |
Middle name | |
Last name | Okamoto |
The Jikei University School of Medicine
Department of Obstetrics and Gynecology
105-8461
3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan
03-3433-1111
aikou@jikei.ac.jp
1st name | Kota |
Middle name | |
Last name | Yokosu |
The Jikei University School of Medicine
Department of Obstetrics and Gynecology
105-8461
3-19-18 Nishishinbashi, Minato-ku, Tokyo, Japan
03-3433-1111
kouta_yokosu@yahoo.co.jp
The Jikei University School of Medicine
None
Self funding
National Cancer Center Hospital East Institutional Review Board
6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, Japan
04-7133-1111
irst@ml.res.ncc.go.jp
NO
2022 | Year | 09 | Month | 20 | Day |
Unpublished
Enrolling by invitation
2022 | Year | 08 | Month | 23 | Day |
2022 | Year | 08 | Month | 23 | Day |
2022 | Year | 09 | Month | 26 | Day |
2026 | Year | 09 | Month | 30 | Day |
2022 | Year | 09 | Month | 13 | Day |
2022 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055568